F-18 FDG PET-CT 检查在复发性脑胶质瘤患者中的应用：与增强 MRI 的对比。

F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.

机构信息

Department of Nuclear Medicine, Medical College Kolkata, Kolkata, India.

出版信息

Eur J Radiol. 2012 Mar;81(3):508-13. doi: 10.1016/j.ejrad.2011.01.080. Epub 2011 Feb 24.

DOI:10.1016/j.ejrad.2011.01.080

PMID:21353420

Abstract

PURPOSE

The purpose of the study was to compare the efficacies of FDG PET-CT and contrast enhanced MRI in detection of recurrent gliomas.

METHODS

Ninety histopathologically proven glioma patients with clinical suspicion of recurrence were evaluated. All patients underwent FDG PET-CT scan and contrast enhanced MRI. Combination of clinical follow up, repeat imaging and biopsy (when available) was taken as gold standard.

RESULTS

Based on gold standard criteria, 59 patients were positive and 31 patients were negative for recurrence. Overall sensitivity and specificity of FDG PET-CT were 70% and 97% respectively whereas that for contrast enhanced MRI was 95% and 23%. FDG PET-CT also has higher accuracy (80%) as compared to MRI (70%). FGD PET-CT has lower sensitivity than MRI in all grades, except for Grade II gliomas where their sensitivities are comparable (95% and 90%). Very low specificity of MRI was observed in all grades of tumour (18-33%). In contrast the specificity of FDG PET-CT was high across all grades (83-100%).

CONCLUSION

FDG PET-CT is a highly specific modality for detecting recurrence in patients with gliomas and can effectively exclude post therapy changes.

摘要

目的

本研究旨在比较 FDG PET-CT 和对比增强 MRI 在检测复发性脑胶质瘤中的疗效。

方法

对 90 例经组织病理学证实的脑胶质瘤患者进行评估，这些患者均有临床复发的疑似症状。所有患者均接受了 FDG PET-CT 扫描和对比增强 MRI 检查。将临床随访、重复成像和活检（如有）的结果结合作为金标准。

结果

根据金标准标准，59 例患者为阳性，31 例患者为阴性。FDG PET-CT 的总体敏感性和特异性分别为 70%和 97%，而对比增强 MRI 的敏感性和特异性分别为 95%和 23%。与 MRI（70%）相比，FDG PET-CT 的准确性（80%）更高。FDG PET-CT 在所有分级中均具有比 MRI 更高的敏感性，除了 II 级胶质瘤，其敏感性相当（95%和 90%）。MRI 在所有分级的肿瘤中特异性均较低（18-33%）。相比之下，FDG PET-CT 在所有分级中的特异性均较高（83-100%）。